Lifeward Ltd. 8-K

What Happened
Lifeward Ltd. (LFWD) filed an 8-K on March 13, 2026 reporting results of its Extraordinary General Meeting held March 12, 2026 (record date Jan 20, 2026). Shareholders representing 7,252,783 ordinary shares (≈39.7% of 18,293,776 outstanding) were present or voted, constituting a quorum. Shareholders approved the Company’s planned issuance of Ordinary Shares in connection with the acquisition of Oratech Pharma, Inc. (the “Oratech Acquisition”) and several related proposals, including director elections, director compensation, an increase to the 2025 Incentive Compensation Plan, an equity grant to CEO Mark Grant, and reappointment of the independent auditor.

Key Details

• Voting quorum: 7,252,783 shares present/voted (≈39.7% of 18,293,776 outstanding).
• Proposal 1 (issuance of Ordinary Shares related to the Oratech Acquisition and related financings): For 1,854,591 / Against 470,084 / Abstain 64,625 / Broker non-votes 4,863,483.
• Proposal 2 (election of two External Directors effective on closing of Oratech Acquisition): For 1,906,767 / Against 409,347 / Abstain 73,186 / Broker non-votes 4,863,483.
• Proposal 6 (reappointment of Kost Forer Gabbay & Kasierer as auditor): For 6,175,644 / Against 573,100 / Abstain 504,039 (no broker non-votes).

Why It Matters
These shareholder approvals clear the way for Lifeward to issue shares to Oramed Pharmaceuticals Inc. and other parties as consideration and financing tied to the Oratech Acquisition, and to implement governance and compensation changes that become effective upon closing. For investors, the approved share issuances and convertible/warrant conversions can increase shares outstanding and affect ownership percentages (i.e., dilution risk), while the director appointments and auditor reappointment are governance actions tied to the transaction.